Skip to textbook content
Doctor’s PassportTextbook
QuestionsFlashcardsBriefsDashboardAccount
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Cancer treatment follow-up and lymphoedema

Obstetrics and gynaecology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Recurrence and treatment toxicity can be emergencies

Major bleeding, bowel obstruction, sepsis, venous thromboembolism, urinary obstruction, spinal cord compression or rapidly spreading cellulitis in a lymphoedematous limb requires acute assessment rather than a routine follow-up appointment.

Action: Assess airway, breathing, circulation, observations and organ-specific red flags; stabilise immediately and involve emergency, acute gynaecology, oncology, surgical, urology or infection teams according to the threatened organ.

Synopsis

Deliver risk-stratified gynaecological cancer follow-up that detects concerning symptoms promptly while actively treating lymphoedema, late toxicity, menopause, sexual, psychological and rehabilitation needs.

  • Follow-up begins with an end-of-treatment summary: cancer site, histology, stage, molecular findings, treatment, residual risks, late effects, medicines, recurrence symptoms and named rapid-access contact.
  • Use tumour- and risk-stratified follow-up. Some low-risk surgically treated cancers can use supported patient-initiated follow-up, while higher-risk disease, fertility-sparing treatment or ongoing systemic therapy needs scheduled specialist surveillance.
  • Do not wait for the next booked visit when new bleeding, blood-stained or offensive discharge, persistent pelvic or abdominal pain, distension, appetite loss, bowel or urinary change, cough, weight loss or a new mass appears.
  • History and focused examination drive recurrence assessment; tumour markers and imaging are ordered when the cancer type, symptoms or treatment protocol provides a defined question rather than as indiscriminate reassurance.
  • Pelvic surgery, groin or pelvic nodal treatment and radiotherapy can impair lymph drainage. Early heaviness, tightness, pitting, limb or genital swelling and recurrent cellulitis should prompt lymphoedema assessment.
  • Exclude recurrence, venous thrombosis, infection, heart, renal or hepatic disease before attributing new swelling solely to treatment-related lymphoedema.
  • Decongestive lymphatic therapy combines compression, skin care, exercise and specialist massage; it controls rather than cures lymphoedema and requires a maintenance self-management phase.
  • Follow-up also treats fatigue, pain, neuropathy, bowel and bladder dysfunction, menopausal symptoms, sexual difficulties, fertility concerns, bone health, work, finances and fear of recurrence.

    • Key red flags

    New heavy vaginal, vulval, urinary or rectal bleeding with haemodynamic change or symptomatic anaemia requires urgent stabilisation and examination.

    Vomiting, absolute constipation, marked distension or colicky abdominal pain after pelvic cancer treatment suggests obstruction and needs same-day surgical assessment.

    New weakness, sensory loss, saddle change, bladder or bowel dysfunction, or severe progressive spinal pain requires emergency assessment for neural compression.

    Sudden breathlessness, chest pain, hypoxia or unilateral limb swelling raises concern for venous thromboembolism and requires immediate investigation.

    A swollen limb or genital area becoming acutely hot, painful and erythematous with fever or rigors suggests cellulitis, which can progress rapidly in lymphoedema.

    Investigation priorities

    01
    Focused recurrence examinationFirst step

    Evaluate the anatomical site suggested by the original cancer and new symptoms.

    Management branches

    End of treatmentBuild a risk-stratified safety net

    Definitive or planned active gynaecological cancer treatment finishes.

    1. Record stage, histology, molecular findings, treatment, toxicities, medicines and residual risks in a summary shared with the patient and primary care.
    2. Assign scheduled, protocol-led or supported patient-initiated follow-up according to recurrence risk, treatment and the person's ability and preference.
    3. Provide named rapid access, explicit recurrence and emergency symptoms, a holistic needs assessment and referrals for unresolved physical, sexual, reproductive or psychological effects.
    Open full textbook →Answer 2 questions
    Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
    Sources

    Sources and review status

    National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.

    • BGCS patient-initiated follow-up recommendations
    • King's College Hospital gynaecological cancer follow-up
    • NHS lymphoedema overview
    • NHS lymphoedema treatment

    Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

    Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom